Susan Altschuller | Vice President of Investor Relations |
Ludwig Hantson | Chief Executive Officer |
Paul Clancy | EVP and Chief Financial Officer |
John Orloff | EVP, Head of Research and Development |
Brian Goff | EVP, Chief Commercial Officer |
Geoffrey Porges | SVB Leerink |
Matthew Harrison | Morgan Stanley |
Chris Raymond | Piper Jaffray |
Martin Auster | Credit Suisse |
Phil Nadeau | Cowen and Company |
Nate Tower | Stifel |
Kennen MacKay | RBC Capital Markets |
Mohit Bansal | Citigroup |
Steven Seedhouse | Raymond James |
Salveen Richter | Goldman Sachs |
Justin Kim | Oppenheimer |
Good morning, and welcome to the Alexion Pharmaceuticals Incorporated Conference Call to discuss Second Quarter 2019 Financial Results. Today's call is being recorded.
For opening remarks and introductions, I would now like to turn the call over to Susan Altschuller, Vice President of Investor Relations. Please go ahead, ma'am.
Thank you, Crystal.